Acurx Pharmaceuticals LLC (NASDAQ:ACXP) continued to move down in the previous trading. Will the stock gain momentum next week?
Market Action
On Thursday, ACXP stock was down 3% to $6.13 with more than 2.69 million shares, compared to its average volume of 5.45 million shares. The stock has moved within a range of $5.82 – 6.84 after opening the trade at $6.74.
Major Trigger:
Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference
Key Highlights:
- Acurx Pharmaceuticals announced that using specimens from a Phase 1 healthy volunteer trial and a novel analysis technique, beneficial changes potentially predictive of lower risk of CDI (Clostridioides difficile Infection) recurrence were associated with ibezapolstat compared to vancomycin. These results were presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy and the Principal Investigator for microbiome aspects of the clinical trial program for ibezapolstat.
- The I-Poster and Abstract presented during the World Microbe Forum 2021 virtual conference held June 20-24, 2021 was entitled: OMICS Evaluation of the Gram-positive Selective Spectrum (GPSS) Antibiotic, ibezapolstat, using Phase 1 Clinical Samples, Predicts a Possible Anti-recurrence Effect in Future Clostridioides difficile Infection Studies.
- This novel OMICS approach which is a comprehensive study to characterize and quantify biological molecules to better understand structure, function and dynamics of an organism or organism community, involved both microbiome analysis using shotgun metagenomics sequencing and determination of bile acid concentrations and may enable better and earlier prediction of anti-CDI recurrence effects for antibiotics in the clinical development pipeline.
 Stock Moves in a Tight Range: How to Trade Now){kind=link}